• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Gregoire Sylvie

    6/14/24 6:23:50 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Gregoire Sylvie

    (Last) (First) (Middle)
    20 PARK PLAZA, SUITE 424

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CervoMed Inc. [ CRVO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/14/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $19.01 06/14/2024 A 5,750 (1) 06/14/2034 Common Stock 5,750 $0 5,750 D
    Explanation of Responses:
    1. On June 14, 2024, in connection with the Reporting Person's election to the Issuer's board of directors at its 2024 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 5,750 shares of the Issuer's common stock under the Issuer's 2015 Equity Incentive Plan, as amended, in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
    /s/ William R. Elder, attorney-in-fact for the Reporting Person 06/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRVO

    DatePrice TargetRatingAnalyst
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    12/17/2024Buy → Neutral
    H.C. Wainwright
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    12/11/2024Overweight → Underweight
    Morgan Stanley
    12/10/2024Buy → Hold
    D. Boral Capital
    12/6/2024$45.00Buy
    ROTH MKM
    12/5/2024$42.00Buy
    H.C. Wainwright
    9/18/2024$55.00Buy
    Chardan Capital Markets
    More analyst ratings

    $CRVO
    SEC Filings

    View All

    CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    12/5/25 4:05:42 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    11/10/25 4:05:32 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by CervoMed Inc.

    S-8 - CervoMed Inc. (0001053691) (Filer)

    11/7/25 5:27:11 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

    Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking oral session at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by C

    12/4/25 5:00:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

    1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response, as assessed by CDR-SB, support neflamapimod mechanism of action and suggest it may act on underlying disease BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company devel

    12/2/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery aft

    11/10/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial and Business Winton Matthew bought $41,430 worth of shares (5,000 units at $8.29), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:46:15 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gregoire Sylvie bought $182,736 worth of shares (21,600 units at $8.46), increasing direct ownership by 0.73% to 1,484,078 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:45:56 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO, GC & Secretary Elder William Robert bought $29,250 worth of shares (3,500 units at $8.36), increasing direct ownership by 39% to 12,500 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:45:32 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CervoMed upgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

    3/13/25 7:28:49 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CervoMed from Buy to Neutral

    12/17/24 7:40:50 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded CervoMed from Buy to Neutral

    12/11/24 7:28:58 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quigley David

    4 - CervoMed Inc. (0001053691) (Issuer)

    12/5/25 6:16:27 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Quigley David

    3 - CervoMed Inc. (0001053691) (Issuer)

    12/5/25 6:15:03 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial and Business Winton Matthew bought $41,430 worth of shares (5,000 units at $8.29), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:46:15 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Leadership Updates

    Live Leadership Updates

    View All

    CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery aft

    11/10/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

    Mr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of David Quigley to its Board of Directors (Board). Mr. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm's Life Sciences and Private Eq

    10/28/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

    BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnology industry, leading organizations through scientific breakthroughs, growth and innovation, and market transformation. "It is a pleasure to welcome Matthew, an experienced and proven leader and organization builder," said John Alam, M.D., Chief Executive Officer of CervoMed. "This appointment comes at a pivotal ti

    10/7/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Financials

    Live finance-specific insights

    View All

    CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

    Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Conference call and webcast today at 8:00 AM ET today to discuss results BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc

    7/28/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

    Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call and webcast on Monday, July 28 at 8:00 AM ET to share new results, including the primary endpoint results at 32-weeks of the Extension phase, from the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bod

    7/24/25 4:05:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

    A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,

    3/10/25 4:05:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CervoMed Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    11/14/24 3:09:10 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CervoMed Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    4/11/24 7:55:23 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

    SC 13G/A - CervoMed Inc. (0001053691) (Subject)

    3/6/24 4:05:55 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care